TY  - JOUR

T1  - DASL-HiCAP (ANZUP1801): The impact of darolutamide on standard therapy for localized very high-risk cancer of the prostate—A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high-risk, clinically localized prostate cancer.

JO  - Journal of Clinical Oncology

PY  - 2020/02/20

AU  - Niazi T

AU  - Williams S

AU  - Davis ID

AU  - Stockler MR

AU  - Martin AJ

AU  - Hague W

AU  - Bracken K

AU  - Gorzeman M

AU  - Roncolato F

AU  - Yip S

AU  - Horvath L et al

ED  - 

DO  - DOI: 10.1200/jco.2020.38.6_suppl.tps385

PB  - American Society of Clinical Oncology (ASCO)

VL  - 38

IS  - 6_suppl

SP  - TPS385

EP  - TPS385

Y2  - 2024/12/22

ER  -